Table 2.

Sequential analysis of SB trans vector-mediated gene expression in human T cells as related to DNA amounts used for nucleofection


pT2/DsRed +/- pUbSB10
Dose, by day
Geometric mean (n = 8)
95% Cl
P(vs 0 μg)
Day 21    
    20 μg   7.07   3.80, 13.16   < .001  
    10 μg   11.04   5.93, 20.56   < .001  
    5 μg   7.03   3.78, 13.09   < .001  
    2.5 μg   3.63   1.95, 6.76   < .001  
    0 μg   0.07   0.04, 0.13   
Day 28    
    20 μg   6.64   3.99, 11.03   < .001  
    10 μg   10.78   6.49, 17.92   < .001  
    5 μg   7.00   4.21, 11.63   < .001  
2.5 μg   3.80   2.29, 6.32   < .001  
0 μg
 
0.12
 
0.07, 0.20
 

 

pT2/DsRed +/- pUbSB10
Dose, by day
Geometric mean (n = 8)
95% Cl
P(vs 0 μg)
Day 21    
    20 μg   7.07   3.80, 13.16   < .001  
    10 μg   11.04   5.93, 20.56   < .001  
    5 μg   7.03   3.78, 13.09   < .001  
    2.5 μg   3.63   1.95, 6.76   < .001  
    0 μg   0.07   0.04, 0.13   
Day 28    
    20 μg   6.64   3.99, 11.03   < .001  
    10 μg   10.78   6.49, 17.92   < .001  
    5 μg   7.00   4.21, 11.63   < .001  
2.5 μg   3.80   2.29, 6.32   < .001  
0 μg
 
0.12
 
0.07, 0.20
 

 

or Create an Account

Close Modal
Close Modal